Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329785 | 0.88 | NR4A1 (0.45) | RAF1EPHX2KDRPLK4AURKA | |
| SCHEMBL2028320 | 0.85 | MAPK14 (0.43) | RAF1EPHX2KDRPLK4AURKA | |
| SCHEMBL1642878 | 0.85 | KDR (0.48) | RAF1MAPTALDH1A1EPHX2KDR | |
| SCHEMBL9979938 | 0.83 | RAF1 (0.38) | RAF1EPHX2KDRPLK4AURKA | |
| SCHEMBL2892341 | 0.83 | RAF1 (0.42) | RAF1EPHX2KDRPLK4AURKA | |
| SCHEMBL12852960 | 0.82 | RAF1 (0.54) | RAF1EPHX2MAPK1KDRPLK4 | |
| SCHEMBL6383415 | 0.81 | KDR (0.47) | RAF1MAPTALDH1A1RAB9AEPHX2 | |
| SCHEMBL22473756 | 0.81 | CYP1A2 (0.49) | RAF1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL3882564 | 0.81 | GABRG2 (0.45) | RAF1EPHX2GABRA1GABRG2GABRB3 | |
| SCHEMBL2886711 | 0.81 | MAPT (0.40) | RAF1MAPTALDH1A1EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409772-B1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2023-06-28 | — | — | EP | disclosed |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11007276-B2 | Intracellular substance transport system and use thereof | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200138973-A1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2020-05-07 | — | — | US | disclosed |
| EP-3330254-A2 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-2548868-B1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA -DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2018-01-24 | — | — | EP | disclosed |
| US-9078933-B2 | Deuterated omega diphenylurea related compounds and intermediates | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-8669369-B2 | Method and process for preparation and production of deuterated Ω-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-11 | — | — | US | disclosed |
| US-8486951-B2 | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. | 2013-02-07 | — | — | US | disclosed |
| EP-2548868-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED -DIPHENYLUREA | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2013-01-23 | — | — | EP | disclosed |
| CN-102803222-A | Method and process for preparation and production of deuterated omega-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | RAF1 25/4885MAPT 3045/4885ALDH1A1 1288/4885 |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885MAPT 2130/4885ALDH1A1 376/4885 |
| US-20200138973-A1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | CTSS, CTSA, CTSB | RAF1 615/4885MAPT 2238/4885ALDH1A1 3078/4885 |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | PNLIP, PDXK, PNP | RAF1 1962/4885MAPT 4536/4885ALDH1A1 2645/4885 |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | ACP1, PACSIN2, PKN2 | RAF1 127/4885MAPT 2880/4885ALDH1A1 3841/4885 |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | RAF1 1043/4885MAPT 4529/4885ALDH1A1 2354/4885 |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | ACP1, PACSIN2, PKN2 | RAF1 122/4885MAPT 3081/4885ALDH1A1 3875/4885 |
| US-11007276-B2 | Intracellular substance transport system and use thereof | CTSS, CTSA, CTSB | RAF1 615/4885MAPT 2238/4885ALDH1A1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.